Satio Inc.
Boston, MA
- UEI
- H8WFVFLRQYN3
- CAGE
- 9DLB1
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 27 Drydock Ave #3, Boston, MA 02210, USA
- Website
- satiopatch.com
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | -$536,094 |
| FY2024 | $0 |
| FY2023 | $4,249,000 |
Contract awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Semi | FA86501825402 | $800,000 |
Similar vendors
About the company
Satio Inc., a for-profit manufacturer of medical devices and diagnostics based in Boston, Massachusetts, operates as a prime contractor on federal research and development contracts focused on drug delivery and point-of-care diagnostic devices. The vendor holds two small-business federal prime contracts and one federal grant sub-award, with combined potential value of $3.7 million across the Department of Health and Human Services (split between the National Institutes of Health and the Office of the Assistant Secretary for Preparedness and Response) and the Department of the Air Force Materiel Command Research Laboratory.
Satio's capability portfolio centers on next-generation transdermal drug delivery and integrated point-of-care diagnostics. The largest award is a $3.5 million firm fixed-price small-business set-aside definitive contract from ARPA-H (NIH-funded) under the SBIR program, awarded September 30, 2023, for development of Digital SatioRx — a low-cost, remotely controllable disposable microneedle transdermal drug delivery device capable of administering any FDA-approved transdermal liquid medication, with completion scheduled for February 3, 2026, and work performed in Boston. A second prime contract from the HHS Office of the Assistant Secretary for Preparedness and Response awarded August 3, 2023 (no set-aside, $212,905.91) funded research and development of a low-cost integrated lateral flow immunoassay and blood collection diagnostic for Ebolavirus. Satio also subcontracts to Semi on a federal grant for SatioDx, an integrated blood-collection device with on-board graphene field-effect transistor capability for biomarker detection in human cognitive performance measurement, awarded April 1, 2024.
Activity remains early-stage and concentrated. Two awards closed in 2023 and one in 2024, all within HHS or DoD research agencies; the portfolio shows no parent contract vehicles or IDIQs. SCI-reported invoicing across federal service contracts above the $150,000 reporting threshold totaled $575 thousand in FY2023 and $2.7 million in FY2024, with Satio delivering work through its own workforce (3.5 FTEs in FY2024, zero subcontractor engagement on SCI-reportable prime contracts). Government-paid hourly rates on federal service contracts ran from a 10th-percentile floor of $151.76/hr to a median of $333.87/hr and a 90th-percentile ceiling of $911.62/hr, reflecting the specialized technical and scientific labor mix. The $3.5 million ARPA-H contract carries a February 2026 completion date and faces recompete exposure within the next twelve months.
Quick answers
Is Satio Inc. registered in SAM.gov?
Satio Inc.'s SAM.gov registration expired on June 16, 2026.
What is Satio Inc.'s CAGE code?
Satio Inc.'s CAGE code is 9DLB1, and its Unique Entity ID (UEI) is H8WFVFLRQYN3.
How much has Satio Inc. received in federal contracts?
Federal contracts obligated $3,712,906 to Satio Inc. in fiscal years 2023 through 2027.
What is Satio Inc.'s most recent federal award?
Satio Inc.'s most recent federal contract award is Development of digital satiorx, a very low cost remotely controllable disposable microneedle transdermal drug… (75N91023C00059), from National Institutes of Health, on September 30, 2023.
On GovTribe
See Satio Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors